Skoči na glavni sadržaj

Croatian Medical Journal, Vol. 66 No. 1, 2025.

Izvorni znanstveni članak

https://doi.org/10.3325/cmj.2025.66.3

Effectiveness of biological therapy in severe asthma: a retrospective real-world study

Marina Lampalo orcid id orcid.org/0000-0001-9264-6922 ; Clinical Department for Lung Diseases Jordanovac, Zagreb University Hospital Center, Zagreb, Croatia *
Anamarija Štajduhar ; Department of Pulmonology, Zagreb University Hospital Center, Zagreb, Croatia
Dina Rnjak orcid id orcid.org/0000-0002-9618-884X ; Department of Pulmonology, Zagreb University Hospital Center, Zagreb, Croatia
Nikola Ferara ; 3 University of Zagreb School of Medicine, Zagreb, Croatia
Hana Safić Stanić ; Croatian Institute for Transfusion Medicine, Zagreb, Croatia
Sanja Popović-Grle ; Department of Pulmonology, Zagreb University Hospital Center, Zagreb, Croatia

* Dopisni autor.

Puni tekst: engleski pdf 542 Kb

str. 3-12

preuzimanja: 6

citiraj

Sažetak

Aim To compare the effectiveness of different biologic
medications for the treatment of severe asthma.
Methods We retrospectively collected data on 74 patients
treated with one of four different biologics (omalizumab,
mepolizumab, reslizumab, or benralizumab) at the Jordanovac Clinic for Pulmonary Diseases, Zagreb, Croatia for
at least two years. The patients were compared in terms of
the number of exacerbations, dose of oral corticosteroids
(OCS), asthma control test (ACT), forced expiratory volume
in 1 second (FEV1
), forced vital capacity, fraction of exhaled
nitric oxide (FeNO), number of blood eosinophils, and total
immunoglobulin E (IgE).
Results All treatment outcome measures, except FeNO,
significantly improved in the two-year period (P<0.001).
The number of acute exacerbations decreased in all
groups. Reslizumab-treated patients showed the greatest
improvement in ACT score, and the omalizumab-treated patients experienced the least (P=0.018). The benralizumab group showed the greatest reduction in eosinophil
number, and the omalizumab group the lowest (P<0.001).
The mepolizumab group showed the greatest improvement in FEV1
.
Conclusion Both anti-IgE and anti-IL-5 treatments effectively reduced exacerbation rates, OCS daily needs, and
symptom burden. Multiple predictive biomarkers are
needed for the best individual monitoring

Ključne riječi

Hrčak ID:

337351

URI

https://hrcak.srce.hr/337351

Datum izdavanja:

29.2.2024.

Posjeta: 15 *